Human papillomavirus vaccination in Tanzanian schoolgirls: cluster-randomized trial comparing 2 vaccine-delivery strategies

Deborah Watson-Jones, Kathy Baisley, Riziki Ponsiano, Francesca Lemme, Pieter Remes, David Ross, Saidi Kapiga, Philippe Mayaud, Silvia de Sanjosé, Daniel Wight, John Changalucha, Richard Hayes, Deborah Watson-Jones, Kathy Baisley, Riziki Ponsiano, Francesca Lemme, Pieter Remes, David Ross, Saidi Kapiga, Philippe Mayaud, Silvia de Sanjosé, Daniel Wight, John Changalucha, Richard Hayes

Abstract

Background: We compared vaccine coverage achieved by 2 different delivery strategies for the quadrivalent human papillomavirus (HPV) vaccine in Tanzanian schoolgirls.

Methods: In a cluster-randomized trial of HPV vaccination conducted in Tanzania, 134 primary schools were randomly assigned to class-based (girls enrolled in primary school grade [class] 6) or age-based (girls born in 1998; 67 schools per arm) vaccine delivery. The primary outcome was coverage by dose.

Results: There were 3352 and 2180 eligible girls in schools randomized to class-based and age-based delivery, respectively. HPV vaccine coverage was 84.7% for dose 1, 81.4% for dose 2, and 76.1% for dose 3. For each dose, coverage was higher in class-based schools than in age-based schools (dose 1: 86.4% vs 82.0% [P = .30]; dose 2: 83.8% vs 77.8% [P = .05]; and dose 3: 78.7% vs 72.1% [P = .04]). Vaccine-related adverse events were rare. Reasons for not vaccinating included absenteeism (6.3%) and parent refusal (6.7%). School absenteeism rates prior to vaccination ranged from 8.1% to 23.5%.

Conclusions: HPV vaccine can be delivered with high coverage in schools in sub-Saharan Africa. Compared with age-based vaccination, class-based vaccination located more eligible pupils and achieved higher coverage. HPV vaccination did not increase absenteeism rates in selected schools. Innovative strategies will be needed to reach out-of-school girls.

Clinical trials registration: NCT01173900.

Figures

Figure 1.
Figure 1.
Study design and participant enrollment. aIncludes the 25 girls in 3 schools that refused whose eligibility could not be reassessed on the day of vaccination. b“Intervention” is defined as the provision of human papillomavirus (HPV) vaccine through 2 different school-based strategies. cBecause the outcome is defined as the receipt of 1, 2, or 3 doses of vaccine by eligible girls, the outcome is known for all eligible girls. Therefore, there is no loss to follow-up in the sense of the outcome being unknown. dSecondary analysis included all schools that were randomized.
Figure 2.
Figure 2.
Coverage for dose 3 in each school, by school type and delivery strategy. Abbreviation: Govt, government.

References

    1. Koutsky L. Epidemiology of genital human papillomavirus infection. Am J Med. 1997;102:3–8.
    1. Walbloomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12–9.
    1. Yang BH, Bray FI, Parkin DM, Sellors JW, Zhang ZF. Cervical cancer as a priority for prevention in different world regions: an evaluation using years of life lost. Int J Cancer. 2004;109:418–24.
    1. Ferlay JSH, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893–917.
    1. GAVI Alliance. GAVI investment strategy. 2008 Human papillomavirus analysis. . Accessed 3 February 2012.
    1. Sankaranarayanan R, Black RJ, Parkin DM. Cancer survival in developing countries. Lyon: International Agency for Research on Cancer; 1998. IARC Scientific Publications no. 145.
    1. Paavonen J, Naud P, Salmeron J, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomized study in young women. Lancet. 2009;374:301–14.
    1. Dillner J, Kjaer SK, et al. Future I/II Study Group. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomized controlled trial. BMJ. 2010;341:c3493.
    1. Reeve C, De La Rue S, Pashen D, Culpan M, Cheffins T. School-based vaccinations delivered by general practice in rural north Queensland: an evaluation of a new human papilloma virus vaccination program. Commun Dis Intell. 2008;32:94–8.
    1. Remes P, Selestine V, Soteli S, et al. Is HPV vaccination in primary schools acceptable in Tanzanian communities [abstract O-09.07] 2011 Program and abstracts of the 27th International Human Papillomavirus Conference, Berlin, Germany, 17–22 September.
    1. Zaba B, Isingo R, Wringe A, Marston M, Slaymaker E, Urassa M. Influence of timing of sexual debut and first marriage on sexual behaviour in later life: findings from four survey rounds in the Kisesa cohort in northern Tanzania. Sex Transm Infect. 2009;85(Suppl 1):i20–6.
    1. Tanzania Demographic and Health Survey 2010. Dar es Salaam: National Bureau of Statistics; April 2011 . Accessed 3 February 2012.
    1. PATH. Child Health and Development Centre (CHDC), and the Uganda National Expanded Program on Immunization (UNEPI). HPV vaccination in Africa: lessons learned from a pilot program in Uganda. Seattle: PATH; 2011. . Accessed 14 December 2011.
    1. LaMontagne DS, Jacob M, Ramos I, Mugisha E, Le NT. Delivery strategies for human papillomavirus vaccinations that achieve high coverage in developing countries [abstract P-712] In: Program and abstracts of the 26th International Papillomavirus Conference, Montreal, Canada, 3–8 July 2010.
    1. Department of Health & Health Protection Agency. Annual HPV vaccine coverage in England in 2009/2010. . Accessed 14 December 2011.
    1. LaMontagne DS, Barge S, Le NT, et al. Human papillomavirus vaccine delivery strategies that achieved high coverage in low- and middle-income countries. Bull World Health Organ. 2011;89:821–30B.
    1. Stokley S, Cohn A, Jain N, McCauley MM. Compliance with recommendations and opportunities for vaccination at ages 11 to 12 years: evaluation of the 2009 national immunization survey-teen. Arch Pediatr Adolesc Med. 2011;165:813–8.
    1. National and state vaccination coverage among adolescents aged 13 through 17 years—United States, 2010. MMWR Morb Mortal Wkly Rep. 2011;60:1117–23.
    1. European Cervical Cancer Association. HPV vaccination across Europe. . Accessed 14 December 2011.
    1. Zimet GD, Weiss TW, Rosenthal SL, Good MB, Vichnin MD. Reasons for non-vaccination against HPV and future vaccination intentions among 19–26 year-old women. BMC Womens Health. 2010;10:27.
    1. Dorleans F, Giambi C, Dematte L, et al. The current state of introduction of human papillomavirus vaccination into national immunisation schedules in Europe: first results of the VENICE2 2010 survey. Euro Surveill. 2010;15 pii = 19730. . Accessed 14 December 2011.
    1. Seruyange R. Child Days Plus—the Uganda experience. Paper presented at: Introduction of new vaccines—Experience Exchange Meeting, Pretoria, 28–30 July 2010.
    1. Mugyenyi P, Mbabazi W, Kabwongera E. Child Days Plus in Uganda: best practices and challenges. Paper presented at: Global Immunization Meeting, New York, 17–19 February 2009 . Accessed 12 November 2011.
    1. Mwandoloma H. Vaccination campaign ends amid reservations. The Guardian. 2 September 2008.
    1. Basic statistics in education: 1994–1998. Dar es Salaam: United Republic of Tanzania; 1999. Ministry of Education and Culture.
    1. UNICEF. . Accessed 2 February 2012.
    1. Quentin W, Watson-Jones D, Changalucha J, et al. Costs of delivering HPV vaccine to school girls in Tanzania [abstract O 05.05] Program and abstracts of the 27th International Papillomavirus Conference (Berlin), Germany. 2011:17–22. Paper presented at: 27th International Papillomavirus Conference, Berlin, 17–22 September 2011 September.
    1. Basic Education Statistics in Tanzania (BEST). 2010 Regional Data. Dar es Salaam: United Republic of Tanzania; 2010. Ministry of Education and Vocational Training. . Accessed 3 February 2012.
    1. Watson-Jones D, Brown J, De Sanjosé S, et al. Cervical HPV prevalence and genotypes in Tanzanian girls and women [abstract P-02.24] Program and abstracts of the 27th International Papillomavirus Conference, Berlin, Germany, 17–22 September 2011.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa